SeaStar Medical’s Selective Cytopheretic Device receives US FDA Breakthrough Device Designation for hepatorenal syndrome

  • Kevin Chung

Press/Media

Period20 Oct 2023

Media coverage

1

Media coverage

  • TitleSeaStar Medical’s Selective Cytopheretic Device receives US FDA Breakthrough Device Designation for hepatorenal syndrome
    Media name/outletPharmaBiz
    Country/TerritoryIndia
    Date20/10/23
    URLwww.pharmabiz.com/NewsDetails.aspx?aid=163140&sid=2
    PersonsKevin Chung
View all 1
View less